Premium
P2‐072: The performance of Aβ5‐X isoforms as novel pharmacodynamic markers of BACE1 inhibition
Author(s) -
Portelius Erik,
Rajendran Lawrence,
Zetterberg Henrik,
Gustavsson Mikael,
Andreasson Ulf,
Olsson Maria,
Brinkmalm Gunnar,
Lundkvist Johan,
Jacobson Laura H.,
Perrot Ludovic,
Neumann Ulf,
Borghys Herman,
Mercken Marc,
Dhuyvetter Deborah,
Jeppsson Fredrik,
Blennow Kaj,
Mattsson Niklas
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.776
Subject(s) - gene isoform , in vivo , chemistry , amyloid precursor protein secretase , pharmacology , amyloid precursor protein , transfection , pharmacokinetics , microbiology and biotechnology , disease , medicine , biochemistry , biology , alzheimer's disease , gene
progressors respectively) (P<0.05). Therewere no differences in composite vascular score, dementia severity (CMMSE and CDR-SOB score), age-related white matter (ARWMC) total score or treatment differences. No differences were noted in APOE status in 6 available data. We found statistically significant increase in GZMB, GZMH, TGFBR3, KLRD1, KIR2DL3 and KIR2DL4 expression (P <0.05) for fast AD-progressors (compared to slow progressors) consistently across 3 time points. Conclusions: Our initial results demonstrate relationship between mRNA levels and fast progression in early AD subjects. This has potential therapeutic implications for the independent role of inflammation and apoptosis in influencing AD progression and we await further confirmation with larger sample analyses.